Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Neoplasm Metastasis 33Multiple Myeloma 23Leukemia, Myeloid, Acute 23Lymphoma 17Colorectal Neoplasms 16Breast Neoplasms 15Pancreatic Neoplasms 12Myelodysplastic Syndromes 12Triple Negative Breast Neoplasms 10Prostatic Neoplasms 10Burkitt Lymphoma 10Sarcoma 9Leukemia, Lymphocytic, Chronic, B-Cell 9Ovarian Neoplasms 8Lymphoma, T-Cell 8Lymphoma, Large B-Cell, Diffuse 8Glioma 7Endometrial Neoplasms 7Carcinoma, Renal Cell 7Neuroblastoma 6Melanoma 6Lymphoma, Non-Hodgkin 6Lung Neoplasms 6Urinary Bladder Neoplasms 5Squamous Cell Carcinoma of Head and Neck 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Myeloproliferative Disorders 5Lymphoma, Follicular 5Fallopian Tube Neoplasms 5Cholangiocarcinoma 5

Interventions

Nivolumab 3Specimen Handling 2Magnetic Resonance Spectroscopy 2X-Rays 1Watchful Waiting 1Taxes 1Sigmoidoscopy 1Proctoscopy 1Phantoms, Imaging 1Paclitaxel 1Observation 1Ipilimumab 1Colonoscopy 1Carboplatin 1CTLA-4 Antigen 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Anal Canal Carcinoma × Biopsy × 30 days × Clear all
NCT03233711 2026-05-29

Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer

National Cancer Institute (NCI)

Phase 3 Active not recruiting
344 enrolled
Gastrointestinal

Anal Canal Carcinoma, Anus Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡